Shelly Malhotra | Vice President Global Access & External Affairs
IAVI

Shelly Malhotra leads the effort to ensure future access to IAVI’s innovations and crafts external engagement and resource mobilization strategies to support IAVI’s core mission. She drives external affairs for fundraising, advocacy and policy, and stakeholder engagement and is the architect of IAVI’s efforts to ensure the affordability, availability, acceptability, and broad adoption of vaccine and therapeutic candidates.

Appearances:

Day 2 - Wednesday 1st April @ 12:10

Panel: Addressing Innovation and Jumpstarting New Projects - The Value & Impact of Product Development Partnerships

Enhancing the PDP Model for Global Access: How can product development partnerships (PDPs) be optimized for sustained vaccine affordability and accessibility in LMICs?
Bridging the R&D Valley of Death: What specific strategies can accelerate the translation of basic research discoveries into viable clinical-stage vaccine projects?
Strengthening Local Biomanufacturing: How can international collaborations effectively transfer technology and build sustainable vaccine manufacturing capacity in LMICs?
Evidence-to-Policy Implementation: What mechanisms are needed for rapid integration of vaccine R&D data and evidence into national and global health policy decisions?
Sustainable Financing for Neglected Diseases: How can diverse funding streams (public, private, philanthropic) be secured to de-risk high-priority, non-commercial vaccine innovation?

Sushant Sahastrabuddhe, Deputy Director General, International Vaccine Institute

Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine

Kimberly Taylor, Senior Scientific Officer, Concept Acceleration Program – Vaccines, NIAID/DMID/OTIPD, NIH

Raman Rao, Chief Executive Officer, Hilleman Laboratories Singapore Pte Ltd

Shelly Malhotra, Vice President Global Access & External Affairs, IAVI

Day 2 - Wednesday 1st April @ 14:40

Panel: Public-Private Partnerships for Pandemic Readiness & Biosecurity: Models That Work

Frameworks and pre-agreements for rapid mobilization of public and private resources
Case studies of successful PPPs (e.g., COVID-19 vaccine partnerships)
Aligning incentives and access obligations across sectors and funders
Evolving global funding roles and the impact of the Pandemic Accord
Building resilient partnerships to ensure equitable innovation and deployment

Holger Kissel, Senior Vice President, BioNTech